Authors

Latest:

Dr. Luis A. Diaz, Jr. on Pembrolizumab For MMR-Deficient Colorectal Cancer

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).

Luis A. Diaz, MD

Latest:

Dr. Diaz on Response Rates for MSI-H and NTRK Fusions in GI Cancer

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.

Luis Carvajal-Carmona, PhD

Latest:

Genetic Analysis of Remote Population May Advance Breast Cancer Prevention and Treatment

Using blood samples collected from the Andean villagers, the laboratory at the UC Davis Genome Center uses a variety of high-throughput genetic analysis techniques to screen for genetic differences.

Luis E. Raez, MD

Latest:

Dr Raez on the FDA Approval of Repotrectinib in NTRK+ Solid Tumors

Luis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.

Luis E. Raez, MD, FACP, FCCP, Memorial Cancer Institute

Luis E. Raez, MD, Memorial Healthcare System

Latest:

TRK Inhibitors in Lung and GI Cancers

Luis G. Paz-Ares, MD, PhD

Latest:

Dr Paz-Ares on the Challenges of NGS in NSCLC

Luis G. Paz-Ares, MD, PhD, discusses the importance of next-generation sequencing and highlights current challenges with NGS for patients with non–small cell lung cancer.

Luis Paz-Ares, MD, PhD

Latest:

Dr Paz-Ares on Tusamitamab Ravtansine in CEACAM5-Positive NSCLC

Luis Paz-Ares, MD, PhD, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial of tusamitamab ravtansine in patients with nonsquamous non–small cell lung cancer with CEACAM5 expression.

Luis Z. Blanco Jr., MD

Latest:

Dr. Blanco on the Role of Pathology in Treatment of Breast Cancer

Luis Z. Blanco Jr., MD, assistant professor of Pathology, Northwestern University, discusses the role a pathologist plays in the treatment of a patient with breast cancer during a presentation at the Lynn Sage Breast Cancer Symposium.

Luisa Iruela-Arispe, PhD

Latest:

Dr. Iruela-Arispe on the Dr. Paul Janssen Award Symposium

Dr. Luisa Iruela-Arispe from University of California, Los Angeles on the Dr. Paul Janssen Award Symposium

Luke Dow, PhD

Latest:

Next Steps for Wnt Research in Colorectal Cancer

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Luke Nordquist,

Latest:

Dr. Nordquist on Matching Patients to Clinical Trials

Luke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.

Luke Nordquist, MD

Latest:

Dr. Luke Nordquist on Who Should Receive Radium-223

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.

Luke Nordquist, MD, FACP

Latest:

Dr. Luke Nordquist on Radium-223 Retreatment

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

Lyn Beamesderfer

Latest:

Putting the Genome to Work in Breast Cancer

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Lyndsay J. Willmott, MD

Latest:

Dr. Willmott on Expanding Genomic Testing in Ovarian Cancer

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Lyndsey Runaas, MD

Latest:

Dr. Runaas on Impactful Targeted Therapies in FLT3-Positive AML

Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

Lynette M. Sholl, MD

Latest:

Dr. Sholl on Challenges With Using Tissue Biopsy for Biomarker Testing in Lung Cancer

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Lynn M. Schuchter, MD

Latest:

Dr. Schuchter Discusses Nivolumab in Melanoma

Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Lynne Lederman, PhD

Latest:

Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia

A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).